Axsome to receive an upfront payment of $66 million, and is eligible to receive sales-based and other milestones totaling up to $101 million Pharmanovia is responsible for all ongoing and future clinical
Axsome Therapeutics (AXSM) Enters License Agreement with Pharmanovia to Expand Commercialization of Sunosi in Europe streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
The Agreement Covers All Existing Territories in Europe and Any Future Launches Across the Region Pharmanovia Will Also Lead All Activities to Support the Launch of Sunosi (solriamfetol) Across Middle